CytoMed Therapeutics Limited Ordinary Shares Working Capital to Net Assets Ratio
CytoMed Therapeutics Limited Ordinary Shares working capital to net assets ratio. CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Working Capital to Net Assets ratio of 43.1% as of December 2025. Working capital of $2.95 Million (current assets of $3.66 Million minus current liabilities of $709.17K) is measured against net assets of $6.85 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check CytoMed Therapeutics Limited Ordinary Sh (GDTC) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Working capital to net assets ratio of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. This chart shows how CytoMed Therapeutics Limited Ordinary Shares's Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of December 2025, the ratio stands at 43.1%, reflecting working capital of $2.95 Million against net assets of $6.85 Million USD. See CytoMed Therapeutics Limited Ordinary Sh (GDTC) defensive interval to measure how many days the company can operate on defensive assets alone.
CytoMed Therapeutics Limited Ordinary Shares Working Capital to Net Assets Ratio by Year (2019–2025)
CytoMed Therapeutics Limited Ordinary Shares working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see CytoMed Therapeutics Limited Ordinary Sh balance sheet assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 43.1% | $2.95 Million | $6.85 Million | $3.66 Million | $709.17K | ▼ -16.5 pp |
| 2024 | 59.6% | $5.39 Million | $9.04 Million | $6.00 Million | $606.49K | ▼ -23.8 pp |
| 2023 | 83.4% | $9.41 Million | $11.27 Million | $10.12 Million | $718.90K | ▲ +368.5 pp |
| 2022 | -285.1% | $-1.68 Million | $589.03K | $2.51 Million | $4.18 Million | ▼ -298.4 pp |
| 2021 | 13.3% | $346.06K | $2.60 Million | $3.29 Million | $2.94 Million | ▲ +277.4 pp |
| 2020 | -264.0% | $-1.26 Million | $476.83K | $1.47 Million | $2.73 Million | ▼ -272.9 pp |
| 2019 | 8.9% | $172.37K | $1.94 Million | $549.01K | $376.65K | — |